Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Chemistry

Biochemistry

Medicine

Cancer Oncology

Pathology

Show all topics

DOI

10.1200/jco.2018.77.7672

License

CC-BY-NC-ND

Other Formats

PDF